218 related articles for article (PubMed ID: 34322995)
1. Inhibition of Janus Kinase 1 synergizes docetaxel sensitivity in prostate cancer cells.
Nalairndran G; Chung I; Abdul Razack AH; Chung FF; Hii LW; Lim WM; Looi CK; Mai CW; Leong CO
J Cell Mol Med; 2021 Sep; 25(17):8187-8200. PubMed ID: 34322995
[TBL] [Abstract][Full Text] [Related]
2. The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe.
Drápela S; Khirsariya P; van Weerden WM; Fedr R; Suchánková T; Búzová D; Červený J; Hampl A; Puhr M; Watson WR; Culig Z; Krejčí L; Paruch K; Souček K
Mol Oncol; 2020 Oct; 14(10):2487-2503. PubMed ID: 32579780
[TBL] [Abstract][Full Text] [Related]
3. Single-Cell Proteomic Profiling Identifies Combined AXL and JAK1 Inhibition as a Novel Therapeutic Strategy for Lung Cancer.
Taverna JA; Hung CN; DeArmond DT; Chen M; Lin CL; Osmulski PA; Gaczynska ME; Wang CM; Lucio ND; Chou CW; Chen CL; Nazarullah A; Lampkin SR; Qiu L; Bearss DJ; Warner S; Whatcott CJ; Mouritsen L; Wade M; Weitman S; Mesa RA; Kirma NB; Chao WT; Huang TH
Cancer Res; 2020 Apr; 80(7):1551-1563. PubMed ID: 31992541
[TBL] [Abstract][Full Text] [Related]
4. Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function.
Parra-Izquierdo I; Melrose AR; Pang J; Lakshmanan HHS; Reitsma SE; Vavilapalli SH; Larson MK; Shatzel JJ; McCarty OJT; Aslan JE
Platelets; 2022 Apr; 33(3):404-415. PubMed ID: 34097573
[TBL] [Abstract][Full Text] [Related]
5. Synergistic anti-tumor effects of Liraglutide, a glucagon-like peptide-1 receptor agonist, along with Docetaxel on LNCaP prostate cancer cell line.
Eftekhari S; Montazeri H; Tarighi P
Eur J Pharmacol; 2020 Jul; 878():173102. PubMed ID: 32283060
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of JAK-STAT Signaling by Baricitinib Reduces Interferon-γ-Induced CXCL10 Production in Human Salivary Gland Ductal Cells.
Aota K; Yamanoi T; Kani K; Ono S; Momota Y; Azuma M
Inflammation; 2021 Feb; 44(1):206-216. PubMed ID: 32772240
[TBL] [Abstract][Full Text] [Related]
7. Janus kinase inhibitors for atopic dermatitis: a promising treatment modality.
Cartron AM; Nguyen TH; Roh YS; Kwatra MM; Kwatra SG
Clin Exp Dermatol; 2021 Jul; 46(5):820-824. PubMed ID: 33484582
[TBL] [Abstract][Full Text] [Related]
8. Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.
Lin HM; Lee BY; Castillo L; Spielman C; Grogan J; Yeung NK; Kench JG; Stricker PD; Haynes AM; Centenera MM; Butler LM; Shreeve SM; Horvath LG; Daly RJ
Prostate; 2018 Mar; 78(4):308-317. PubMed ID: 29314097
[TBL] [Abstract][Full Text] [Related]
9. Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantation.
Persaud SP; Ritchey JK; Kim S; Lim S; Ruminski PG; Cooper ML; Rettig MP; Choi J; DiPersio JF
J Clin Invest; 2021 Dec; 131(24):. PubMed ID: 34730109
[TBL] [Abstract][Full Text] [Related]
10. The JAK1/2 inhibitor baricitinib suppresses eosinophil effector function and restricts allergen-induced airway eosinophilia.
Luschnig P; Kienzl M; Roula D; Pilic J; Atallah R; Heinemann A; Sturm EM
Biochem Pharmacol; 2021 Oct; 192():114690. PubMed ID: 34274356
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation.
Gu L; Talati P; Vogiatzi P; Romero-Weaver AL; Abdulghani J; Liao Z; Leiby B; Hoang DT; Mirtti T; Alanen K; Zinda M; Huszar D; Nevalainen MT
Mol Cancer Ther; 2014 May; 13(5):1246-58. PubMed ID: 24577942
[TBL] [Abstract][Full Text] [Related]
12. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
Li X; Wu JB; Chung LW; Huang WC
Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
[TBL] [Abstract][Full Text] [Related]
13. JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment.
Zhang Y; Liang R; Chen CW; Mallano T; Dees C; Distler A; Reich A; Bergmann C; Ramming A; Gelse K; Mielenz D; Distler O; Schett G; Distler JHW
Ann Rheum Dis; 2017 Aug; 76(8):1467-1475. PubMed ID: 28478401
[TBL] [Abstract][Full Text] [Related]
14. GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells.
Karanika S; Karantanos T; Kurosaka S; Wang J; Hirayama T; Yang G; Park S; Golstov AA; Tanimoto R; Li L; Thompson TC
Mol Cancer; 2015 Jun; 14():122. PubMed ID: 26084402
[TBL] [Abstract][Full Text] [Related]
15. The safety of baricitinib in patients with rheumatoid arthritis.
Honda S; Harigai M
Expert Opin Drug Saf; 2020 May; 19(5):545-551. PubMed ID: 32174196
[No Abstract] [Full Text] [Related]
16. Phosphoinositide-dependent Kinase-1 (PDPK1) regulates serum/glucocorticoid-regulated Kinase 3 (SGK3) for prostate cancer cell survival.
Nalairndran G; Hassan Abdul Razack A; Mai CW; Fei-Lei Chung F; Chan KK; Hii LW; Lim WM; Chung I; Leong CO
J Cell Mol Med; 2020 Oct; 24(20):12188-12198. PubMed ID: 32926495
[TBL] [Abstract][Full Text] [Related]
17. Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer.
Kroon J; Puhr M; Buijs JT; van der Horst G; Hemmer DM; Marijt KA; Hwang MS; Masood M; Grimm S; Storm G; Metselaar JM; Meijer OC; Culig Z; van der Pluijm G
Endocr Relat Cancer; 2016 Jan; 23(1):35-45. PubMed ID: 26483423
[TBL] [Abstract][Full Text] [Related]
18. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
Traves PG; Murray B; Campigotto F; Galien R; Meng A; Di Paolo JA
Ann Rheum Dis; 2021 Jul; 80(7):865-875. PubMed ID: 33741556
[TBL] [Abstract][Full Text] [Related]
19. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition.
Dowty ME; Lin TH; Jesson MI; Hegen M; Martin DA; Katkade V; Menon S; Telliez JB
Pharmacol Res Perspect; 2019 Dec; 7(6):e00537. PubMed ID: 31832202
[TBL] [Abstract][Full Text] [Related]
20. Baricitinib: therapeutic potential for moderate to severe atopic dermatitis.
Calabrese L; Malvaso D; Chiricozzi A; Tambone S; D'Urso DF; Guerriero C; Peris K
Expert Opin Investig Drugs; 2020 Oct; 29(10):1089-1098. PubMed ID: 32703039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]